Zhan-Hong Chen
Overview
Explore the profile of Zhan-Hong Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1301
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tian T, Chen Z, Zheng Z, Liu Y, Zhao Q, Liu Y, et al.
Theranostics
. 2020 Jun;
10(13):5998-6010.
PMID: 32483433
Metastatic colorectal cancer (CRC) is a lethal disease; however, the underlying molecular mechanisms remain unclear and require further study. RNA-Seq, PCR, Western blotting, immunohistochemistry, ChIP and RNAi assays were performed...
12.
Yang D, Chen Z, Yu K, Lu J, Wu Q, Wang Y, et al.
Front Oncol
. 2020 Mar;
10:115.
PMID: 32175271
Methyltransferase-like 3 (METTL3), a major component of the N6-methyladenosine (m6A) methyltransferase complex, has been suggested to function as an oncogene in several cancers. However, its biological mechanism and the involved...
13.
Yang D, Chen Z, Wang D, Yu H, Lu J, Xu R, et al.
J Cancer
. 2020 Jan;
11(5):1063-1074.
PMID: 31956353
The aim of our research was to assess the prognostic value of the apolipoprotein B (ApoB) to apolipoprotein A-I (ApoA-I) ratio (ApoB/ApoA-I) in metastatic colorectal cancer (mCRC) patients. We randomly...
14.
Wang Y, Lu J, Wang F, Wang Y, He M, Wu Q, et al.
Cancer Lett
. 2020 Jan;
473:74-89.
PMID: 31904482
Gastrointestinal cancer causes countless deaths every year due to therapeutic resistance. However, whether metabolic alterations contribute to chemoresistance is not well understood. In this study, we report that fatty acid...
15.
Wei L, Wen J, Chen J, Ma X, Wu D, Chen Z, et al.
World J Gastroenterol
. 2019 Oct;
25(37):5590-5603.
PMID: 31602160
Background: Pancreatic cancer is a major cause of cancer-related death, with a 5-year overall survival rate being below 5%. The main causes of poor prognosis in pancreatic cancer include easy...
16.
Zhou H, Wang X, Jiang X, Qian Z, Chen T, Hu Y, et al.
Breast Cancer Res Treat
. 2019 Aug;
178(1):63-73.
PMID: 31364001
Background: Chromosomal instabilities (CIN) of plasma cell-free DNA (cfDNA) are common in breast cancer. We aimed to investigate the value of cfDNA CIN in monitoring the breast cancer relapse and...
17.
Zhao L, Yang D, Ma X, Liu M, Wu D, Zhang X, et al.
J Cancer
. 2019 Jul;
10(10):2299-2311.
PMID: 31258733
: Lymphocytes were reported to play a significant part in host anticancer immune responses and influence tumour prognosis. Few studies have focused on the prognostic values of aspartate aminotransferase (AST)...
18.
Li T, Hu P, Zuo Z, Lin J, Li X, Wu Q, et al.
Mol Cancer
. 2019 Jun;
18(1):112.
PMID: 31230592
Background: Colorectal carcinoma (CRC) is one of the most common malignant tumors, and its main cause of death is tumor metastasis. RNA N-methyladenosine (mA) is an emerging regulatory mechanism for...
19.
Lei L, Ye W, Zheng L, Huang P, Shi L, Huang J, et al.
Onco Targets Ther
. 2019 May;
12:2931-2936.
PMID: 31118664
Metastatic breast cancer (MBC) is the most life-threatening disease in women worldwide. HER2-mutated breast carcinoma has been reported to benefit from HER2-targeted tyrosine kinase inhibitors recently. Here, we presented a...
20.
Chen Z, Qi J, Wu Q, Lu J, Liu Z, Wang Y, et al.
J Exp Clin Cancer Res
. 2019 May;
38(1):196.
PMID: 31088567
Background: Deregulation of protein translation control is a hallmark of cancers. Eukaryotic initiation factor 4A2 (EIF4A2) is required for mRNA binding to ribosome and plays an important role in translation...